A “MAJOR” expansion to Clare Holland House in Bruce will see more Canberrans living their final days with dignity, says CEO of The Snow Foundation, Georgina Byron, who has partnered with the Australian and ACT government for the […]
A RESEARCH team from ANU and the University of Queensland has designed and made a molecule derived from a human protein that kills the parasite which causes malaria.Treatments for malaria, a disease that kills a person every 90 seconds, are becoming less effective because of drug resistance and there is a risk to the future control of the disease.
Lead researcher associate Prof Brendan McMorran from ANU says the team is a step closer to developing a new and effective treatment for malaria.
“We have designed and created a small fragment of a human protein called Platelet factor 4, known as PF4, that can kill the microbial parasite that causes malaria, Plasmodium,” he says.
“PF4, which my research group at ANU identified in previous work, is the only human protein known to kill malarial parasites.”
The protein is relatively large and not suited to use as a treatment, so the team copied parts of the protein that are critical for terminating the malarial parasites into a smaller molecule, otherwise known as a peptide.
“We have shown that this peptide kills the parasite in a way that is completely different to how current antimalarial drugs work,” he says.
“This is important because finding new ways to kill the parasite will help us overcome the drug-resistance problems.”
The study involves expertise from several disciplines from the John Curtin School of Medical Research, the ANU Research School of Biology and the Institute for Molecular Bioscience at the University of Queensland.
The researchers tested the peptide’s effectiveness at killing the malarial parasite cultured in human red cells under laboratory conditions.
The team will develop more potent versions of the peptide that can be used as new treatments for malaria.
“To do this, we plan to modify the peptide to include new functions that target other vulnerable parts of the parasite, and make the peptide more suited to being administered to people,” Dr McMorran says.
The research is published in “Cell Chemical Biology“.